REDWOOD CITY, Calif., Aug. 23, 2011 /PRNewswire/ — RelievantMedsystems, Inc.,
today announced the appointment of Alex DiNello to the position of
president and chief executive officer and as a member of the
company’s board of directors. The Company recently received FDA
approval of an Investigational Device Exemption (IDE) to begin its
SMART pivotal trial. The Surgical Multi-center Assessment of RF
Ablation for the Treatment of Vertebrogenic Back Pain (SMART) trial
is a prospective, randomized, double-blind, sham-controlled
investigation evaluating the reduction of pain in patients with
chronic axial low back pain that is targeting to enroll 200
subjects.
“As a minimally invasive therapy for those who suffer from
inadequately treated chronic low back pain, the Intracept System
has the potential to significantly and positively affect people’s
lives,” said Mr. DiNello. “I joined the Relievant team because I
believe the Intracept System brings a highly innovative,
differentiated technology requiring no implant to spine specialists
and their millions of patients who suffer from this debilitating
and painful condition.”
Mr. DiNello brings over 20 years of experience in the medical
device industry, including 18 years focusing on spinal therapies
and related medical devices. He has extensive product development,
clinical, and commercialization experience including over 60
products successfully launched across the globe. Prior to joining
Relievant, DiNello served as vice president and general manager for
Medtronic Kyphon. Prior to that, he served as vice president of
research and development for Medtronic Kyphon. Previous to that, he
was vice president of research and development for Abbott Spine. He
also served as vice president of strategic development and research
and development at DePuy Spine, a Johnson & Johnson
company.
“Alex is uniquely suited to lead the company during this
critical phase of exec
‘/>”/>
